We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Angiogenesis Inhibitor SU5416 a Safe Addition to Therapy for Colorectal Cancer

Aug 1, 2000
Volume: 
9
Issue: 
8
  • Gastrointestinal Cancer

LOS ANGELES—A new angiogenesis signaling inhibitor called SU5416
can be safely used with 5-fluorouracil (5-FU) and leucovorin to treat
metastatic colorectal cancer, according to results presented at the
36th annual meeting of the American Society of Clinical Oncology (ASCO).

SU5416 blocks the vascular endothelial growth factor receptor
(VEGF-R). Without VEGF-R, tumors may lose the ability to form
nourishing blood vessels. It is thought that as a result, SU5416 may
starve tumors and keep them from growing.

Combination Phase I-II Trial

The research, presented by scientists from the University of
California at Los Angeles (UCLA) School of Medicine and from SUGEN,
Inc., South San Francisco, California, was a combination phase I and
phase II trial of two dose levels of SU5416 (85 mg/m² and 145
mg/m²) administered twice a week combined with 5-FU and
leucovorin.

The 28 patients had untreated metastatic colorectal cancer. Of these,
13 received 5-FU/leucovorin according to the Mayo Clinic regimen (425
mg/m² intravenous push of 5-FU and 20 mg/m² intravenous
push of leucovorin), and 15 according to the Roswell Park regimen
(500 mg/m² of leucovorin as a 2-hour infusion with a 600
mg/m² intravenous push of 5-FU halfway through).

The goal of the study was to determine whether SU5416 could be
administered safely with 5-FU and leucovorin.

The results showed that SU5416 could indeed be safely combined with
the other two agents. No dose-limiting toxicities were attributed to
SU5416. In an interview with ONI, Lee Rosen, MD, assistant
professor, Division of Hematology and Oncology, and director, Cancer
Therapy Development Program, UCLA’s Jonsson Cancer Center, said
that SU5416 caused mild headaches in some patients. Otherwise, no
clearcut toxicities were attributable to SU5416.

“We did see about a 15% to 20% incidence of catheter-related
deep vein thrombosis, but it was never really clear whether it was
due to the catheter, the cancer, or the drug,” Dr. Rosen said.
“After we started prophylactic low doses of anticoagulation, we
saw almost no new clots.”

Some patients did experience the typical grade 3 and 4 toxicities
expected with 5-FU and leucovorin, including severe nausea, vomiting,
diarrhea, mucositis, and neutropenia. The rates of these were lower
with the Roswell Park regimen.

Of the 28 patients who started therapy, 41% had a complete or partial
response, with their tumors shrinking at least 50%. Twenty-six of the
28 patients are still alive, and three patients have remained on
therapy for more than a year. The median time to progression in this
trial was 9.3 months. This compares favorably with 5-FU alone, which
typically has a median time to progression of 6 months, Dr. Rosen
told ONI.

SU5416 is now being evaluated in a phase III trial for advanced
colorectal cancer. The trial pits 5-FU plus leucovorin alone against
the two agents plus SU5416.

SU5416 Well Tolerated

The researchers concluded that patients tolerated SU5416 combined
with 5-FU and leucovorin well, with most side effects due to the
latter two agents. The Roswell Park regimen did result in fewer
toxicities and is preferable for that reason.

Dr. Rosen told ONI that the study showed two important points.
“One is that very clearly you can give full doses of
chemotherapy with the angiogenesis inhibitor. It’s safe;
it’s well tolerated for long periods of time,” he said.

Second, this and other studies of SU5416, combined with the results
of a Genentech study with anti-VEGF, also reported at ASCO, seem to
provide proof of principle that interfering with angiogenesis by
blocking VEGF or VEGF-R is an appropriate approach to some cancers.

“Hopefully, within the next year and a half or so, we’ll
have the answer to whether this particular angiogenesis inhibitor, by
manipulating VEGF, will prolong patient survival, which is what
it’s all about,” he said.

Related Articles

  • ctDNA Increase May Predict Regorafenib Response in Advanced CRC
  • Inhibit CXCR4 to Treat CRC and Pancreatic Cancer
  • Short-Acting CCBs May Increase Risk of Pancreatic Cancer
  • A3AR Agonists May Help Prevent Chemotherapy-Induced Neuropathic Pain
  • Deep Learning–Based Tissue Analysis May Benefit Colorectal Cancer Patients

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.